NEW RESEARCH offers insight into COVID-19 outcomes in cystic fibrosis transplant recipients, highlighting lung function as a potential factor linked to disease severity.
Lung Function May Shape COVID-19 Outcomes
Cystic fibrosis is a genetic condition that primarily affects the lungs and digestive system, often requiring solid organ transplantation in advanced cases. Understanding how SARS-CoV-2 affects this vulnerable group is critical for guiding patient care.
Researchers compiled data from 526 cystic fibrosis transplant recipients across 19 countries who contracted SARS-CoV-2. The median age of participants was 36 years, and the median time since transplant was almost six years. Hospitalisation or death following infection was the primary measure of severity, while changes in lung function over the year after infection were assessed as a secondary outcome.
The study found that the interval since transplantation did not significantly influence the odds of hospitalisation or death. Statistical analysis showed an odds ratio close to 1, indicating no meaningful impact of transplant timing on outcomes from SARS-CoV-2 infection. Conversely, higher baseline lung function, measured by predicted percentage forced expiratory volume in one second (ppFEV1), was linked to a lower likelihood of severe outcomes. In a subgroup analysis, lung function trajectory did not change significantly over the year following SARS-CoV-2 infection. However, patients with more advanced lung disease remain at increased risk and require close monitoring.
Implications and Limitations
These findings highlight the importance of baseline lung assessment in managing cystic fibrosis transplant recipients during the pandemic. While timing of transplant appears less critical than lung health, individuals with lower ppFEV1 should continue to receive vigilant monitoring and preventive care to reduce the risk of severe complications from SARS-CoV-2. The findings suggest that post-infection lung function may remain stable in some patients and could help inform follow-up strategies and patient counselling.
However, most participants were several years past their transplant, with a median time of 5.8 years (interquartile range 3.3–10.8). Additional research is needed to assess COVID-19 outcomes in patients who are closer to their transplantation date, as risk profiles could differ in the early post-transplant period.
Reference
Semenchuk J et al. Outcomes of SARS-CoV-2 infection post-solid organ transplantation in the cystic fibrosis population. J Cyst Fibros. 2026;DOI:10.1016/j.jcf.2026.02.009
Featured image: Leungchopan on Adobe stock
